Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$4.26
−$0.03 · -0.70%
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Previous close
$4.26
−$0.03 · -0.70%
Regular session · ET · Market data may be delayed.
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Day range
Current $4.26
52-week range
Current $4.26
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Buy
Favorable setup — positive multi-factor alignment
Valuation
85
Deep Value
Sentiment
57
Mixed
Risk
46
Elevated Risk
Momentum
74
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Day range
Current $4.26
52-week range
Current $4.26
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 296.15M USD | 351.41M USD | 442.74M USD | 410.6M USD | 413.75M USD |
| Cost of goods sold | — | 7.55M USD | 6.15M USD | 1.42M USD | 70.41M USD |
| Gross profit | 296.15M USD | 343.86M USD | 436.59M USD | 409.18M USD | 343.35M USD |
| Research and development | 95.14M USD | 111.42M USD | 116.09M USD | 44.27M USD | 70.41M USD |
| Selling, general, and administrative | 82.26M USD | — | — | 115.99M USD | — |
| Operating expenses | 177.39M USD | 250.73M USD | 1.38B USD | 158.84M USD | 111.09M USD |
| Interest income | 4.08M USD | 4.47M USD | 18.97M USD | 9.5M USD | 726K USD |
| Interest expense | 32.75M USD | 33.03M USD | 21.63M USD | 7.6M USD | 31.15M USD |
| Depreciation and amortization | 1.88M USD | 2.01M USD | 1.58M USD | 1.42M USD | 1.52M USD |
| Operating income | 118.76M USD | 93.12M USD | −945.43M USD | 250.34M USD | 232.26M USD |
| Net income | 24.02M USD | 880K USD | −1B USD | 175.07M USD | 528.45M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.68
56.81% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 2, 2019 | 597:500 | — | — |
Effective Apr 2, 2019
597:500
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI25.16M0.22%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI20.23M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM17.92M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF7.01M0.01%93.7B USD0.05%$242.66+0.14%
Schwab Fundamental U.S. Small Company Index ETFFNDA6.99M0.08%9.06B USD0.25%$37.20+0.46%
iShares Russell 2000 Growth ETFIWO6M0.04%14.58B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB5M0.05%10.72B USD0.44%$211.92-0.88%
Pacer US Small Cap Cash Cows ETFCALF4.67M0.12%3.96B USD0.59%$57.43-0.73%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSchwab Fundamental U.S. Small Company Index ETFFNDAiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBPacer US Small Cap Cash Cows ETFCALFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
